drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting GPRC5D and CD19, redirecting T-cell cytotoxicity against malignant plasma cells and B-lineage/myeloma subclones.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor recognizing GPRC5D and CD19 on malignant plasma cells and B-lineage/myeloma subclones; antigen engagement activates CAR signaling, triggering T‑cell activation, cytokine release, and perforin/granzyme-mediated cytotoxicity to eradicate tumor cells and reduce antigen escape.
drug_name
GPRC5D-CD19 CAR T cells
nct_id_drug_ref
NCT06298266